LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion

BACKGROUND: Targeting EBV-proteins with mRNA vaccines is a promising way to treat EBV-related tumors like nasopharyngeal carcinoma (NPC). We assume that it may sensitize tumors to immune checkpoint inhibitors. RESULTS: We developed an LMP2-mRNA lipid nanoparticle (C2@mLMP2) that can be delivered to...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Yu, Tian, Miaomiao, Huang, Juan, Li, Yueyi, Li, Guangqi, Li, Xue, Jiang, Zedong, Song, Xiangrong, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486025/
https://www.ncbi.nlm.nih.gov/pubmed/37679769
http://dx.doi.org/10.1186/s12951-023-02069-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486025/
https://www.ncbi.nlm.nih.gov/pubmed/37679769
http://dx.doi.org/10.1186/s12951-023-02069-w

Ejemplares similares